Biosense Webster, Inc.
Fact Sheet

Biosense Webster, Inc. is the global leader in the science of diagnosing and treating heart rhythm disorders. The company partners with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide. Ongoing research and development at Biosense Webster has given electrophysiologists access to three-dimensional, real-time, color-coded views into the heart’s electrical activity, allowing diagnosis and treatment with increasing precision. Guided by clinician driven insights focused on addressing unmet patient needs, Biosense Webster has pioneered innovative technological advancements in the field of electrophysiology for the past 20 years.

A Worldwide Leader in Electrophysiology
Biosense Webster established its leadership in electrophysiology with the development of the world’s first real-time, three-dimensional cardiac mapping and navigation technology, and the world’s first electrophysiology catheter. The introduction of the company’s CARTO® 3 System in 2009 revolutionized 3D mapping technology by increasing the accuracy, speed, and efficiency of the procedure through Advanced Catheter Location (ACL) technology,1 Fast Anatomical Mapping (FAM), and the CONNECTION OF CHOICE™ patient interface unit. The company’s foundational experience in catheter ablation technologies also led to the Food and Drug Administration (FDA) approval in 2009 of the first therapeutic ablation catheter to address atrial fibrillation in the United States, the NAVISTAR® THERMOCOOL® Catheter.2 Continued innovation and rigorous clinical evaluation led to the approval in February 2014 of the THERMOCOOL® SMARTOUCH® Catheter, the first ablation catheter approved in the U.S. by the FDA to feature direct contact force technology.

A Strong History of Innovation

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>The CARTO® System enables 3D mapping and navigation for the first time in Europe &amp; the U.S.</td>
<td>The NAVISTAR® Catheter, the first combination diagnostic &amp; ablation catheter is introduced in Europe</td>
<td>The ThermoCool® Catheter, the world’s first irrigated catheter is introduced</td>
<td>The LASSO® Catheter, the world’s first circular mapping catheter is introduced</td>
<td>The CARTO® 3 System revolutionizes 3D mapping technology by increasing accuracy, speed, and efficiency</td>
<td>The ThermoCool® Catheter is the first catheter approved in the U.S. for treatment of Afib</td>
<td>The IDE trial for the nMARQ™ Catheter, the world’s first irrigated multi-ablation catheter, is initiated in the U.S.1 (CE Marked in Europe in 2013)</td>
<td>The ThermoCool® SMARTOUCH® Catheter is FDA approved in the U.S. (CE Marked in Europe in 2010)</td>
</tr>
</tbody>
</table>

1 Data on file
3 The nMARQ™ Circular Catheter is approved for investigational device use only and is not available for sale in the U.S. THERMOCOOL® Navigation Catheters are approved for drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with CARTO® Systems (excluding NAVISTAR® RMT THERMOCOOL® Catheter).

©Biosense Webster, Inc. 2014

Media Contact: Janet Kim
909.839.7275 | jkim50@its.jnj.com